AMBOSS's LiSA performed best in clinical AI study
It achieved top safety-weighted performance with the fewest severe errors, outperforming generalist models in the Stanford-Harvard study.
See the latest news and media coverage for AMBOSS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Digital medical education and clinical decision-support platform
amboss.comLast updated
In short: AMBOSS raised €240M, acquired NEJM Knowledge+ and Novaheal, and topped clinical AI safety benchmarks.
It achieved top safety-weighted performance with the fewest severe errors, outperforming generalist models in the Stanford-Harvard study.
Forbes highlights the NOHARM study where AMBOSS AI Mode Clinical Care (LiSA 1.0) outperforms others due to its curated medical knowledge base. AMBOSS prioritizes patient safety and responsible AI.
It serves as an AI study copilot integrated into the platform, providing trusted explanations, targeted practice, and progress tracking for medical learners.
It topped clinical safety among 31 AI systems in Stanford-Harvard benchmark using 100 real cases across 10 specialties. Performance prioritized patient safety and context-aware reasoning.
Bloomberg: Berlin-based Amboss, which makes study guide apps for medical students and online databases for clinicians, raised €240M, sources say at an €800M+ valuation...
A core feature at Amboss is the integration of Artificial Intelligence. The platform combines its specific knowledge database with...
Track AMBOSS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AMBOSS and other trending companies.